DTXM.F logo

Deltex Medical Group OTCPK:DTXM.F Stock Report

Last Price

US$0.003

Market Cap

US$3.3m

7D

0%

1Y

-99.3%

Updated

16 Aug, 2024

Data

Company Financials

Deltex Medical Group plc

OTCPK:DTXM.F Stock Report

Market Cap: US$3.3m

DTXM.F Stock Overview

Manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. More details

DTXM.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Deltex Medical Group plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Deltex Medical Group
Historical stock prices
Current Share PriceUK£0.003
52 Week HighUK£0.43
52 Week LowUK£0.0013
Beta0.81
1 Month Change0%
3 Month Changen/a
1 Year Change-99.30%
3 Year Changen/a
5 Year Changen/a
Change since IPO-99.43%

Recent News & Updates

Recent updates

Shareholder Returns

DTXM.FUS Medical EquipmentUS Market
7D0%2.0%-0.5%
1Y-99.3%9.8%23.2%

Return vs Industry: DTXM.F underperformed the US Medical Equipment industry which returned 9.3% over the past year.

Return vs Market: DTXM.F underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is DTXM.F's price volatile compared to industry and market?
DTXM.F volatility
DTXM.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.4%
10% most volatile stocks in US Market18.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: DTXM.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DTXM.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200037Andy Mearswww.deltexmedical.com

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; DoppLink, a patient interface cable that enhances signal processing; and PressureWave, a pulse contour analysis algorithm. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting; and TrueVue monitor.

Deltex Medical Group plc Fundamentals Summary

How do Deltex Medical Group's earnings and revenue compare to its market cap?
DTXM.F fundamental statistics
Market capUS$3.31m
Earnings (TTM)-US$1.66m
Revenue (TTM)US$2.30m

1.4x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTXM.F income statement (TTM)
RevenueUK£1.78m
Cost of RevenueUK£651.00k
Gross ProfitUK£1.13m
Other ExpensesUK£2.41m
Earnings-UK£1.28m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.00068
Gross Margin63.34%
Net Profit Margin-72.18%
Debt/Equity Ratio55.5%

How did DTXM.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/16 22:21
End of Day Share Price 2024/05/20 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Deltex Medical Group plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SimmsArden Partners Plc.
Francesco GregoriCharles Stanley & Co. Ltd.
Francesco GregoriCharles Stanley Securities